期刊文献+

9-硝基喜树碱半固体脂质纳米粒的制备及大鼠的药动学研究 被引量:14

Preparation of 9-Nitrocamptothecin Semi-solid Lipid Nanoparticles and Pharmacokinetics in Rats
暂未订购
导出
摘要 采用高温乳化蒸发-低温固化法制备9-硝基喜树碱(1)半固体脂质纳米粒,并考察其形态、粒径、包封率、z电位及大鼠静脉给药后体内药物动力学行为。结果表明,1半固体脂质纳米粒为圆形,具有明显可见的亲水性聚乙二醇“外壳”,粒径为223.3~249.1nm,包封率为77.9%~83.5%,z电位为-28.4~-22.2mV。分别用1半固体脂质纳米粒和溶液对大鼠静脉给药,体内药物动力学参数分别为:t1/2 (14.9±0.3)h和(1.2±0.6)h,AUC0~t(486±37)mg·h·L-1和(117±64)mg·h·L-1,MRT (19.3±0.7)h和(1.7±1.0)h。表明1半固体脂质纳米粒可延长体循环时间,提高生物利用度。 Nitrocamptothecin(1)semi-solid lipid nanoparticles(SSLN)were prepared by emulsification at a hightemperature and solidification at a low temperature. The shape, particle size, encapsulation efficiency, z potential andpharmacokinetics in rats of 1 SSLN were investigated. The results showed that the prepared SSLN was spherical andcovered with PEG chain on the surface. The size of the particles was 223.3~249.1nm and encapsulation efficiency was77.9%~83.5%. The z potential was -28.4~-22.2mV. 1 SSLN and its solution were intravenously injected into rats,respectively. And their pharmacokinetic parameters were as follows: t1/2 (14.9±0.3)h and(1.2±0.6)h, AUC0~t(486±37)mg·h·L-1 and (117±64)mg·h·L-1, MRT (19.3±0.7)h and (1.7±1.0)h. It indicated that 1 SSLN couldprolong circulation time in blood and improve drug bioavailability.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2004年第10期599-602,共4页 Chinese Journal of Pharmaceuticals
关键词 9-硝基喜树碱 半固体脂质纳米粒 药物动力学 nitrocamptothecin semi-solid lipid nanoparticles pharmacokinetics
  • 相关文献

参考文献4

  • 1Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer teatment [J]. Br J Cancer, 1996, 74(3): 327-338.
  • 2Sands H, Mishra A, StoecKler JD, et al. Preclinical activity of an i.v. formulation of rubitecan in IDD-PTM against human solid tumor xenografts [J]. Anti-Cancer Drugs, 2002, 13 (9):965-975.
  • 3Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs [J]. Int J Pharm, 2002, 242(1-2) : 121-128.
  • 4李柯,钟大放.高效液相色谱法测定大鼠组织及血浆中9-硝基喜树碱含量[J].药学学报,2003,38(2):124-128. 被引量:18

二级参考文献6

  • 1Sawada S, Yokokura T. Synthesis of CPT-11 [J]. Ann NY Acad Sci, 1996,803:13-28.
  • 2Verschraegen CF, Natelson EA, Giovanella BC, et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor [J]. Anti Cancer Drugs, 1998, 9(1):36-44.
  • 3Ahmed AE, Jacob S, Giovanella BC, et al. Comparative disposition of the antineoplastic agent 9-nitrocamptothecin and the inactive isomer 12-nitrocamptothecin in CASE-bearing nude mice: effect of route of administration on tissue distribution [J]. Cancer Chemother Pharmacol, 1997,41(1):29-36.
  • 4Koshkina NV, Gilbert BE, Waldrep JC, et al. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice [J]. Cancer Chemother Pharmacol, 1999,44(3):187-192.
  • 5Stehlin JS Jr, Natelson EA, Hinz HR, et al. Phase I clinical trial and pharmacokinetics resulted with oral administration of 20(S)-camptothecin [A]. Potmesil M. Camptothecins: New Anticancer Agent [M]. Boca Raton: CRC Press, 1995.59-65.
  • 6Ahmed AE, Jacob S, Giovanella BC, et al. Influence of route of administration of 3H-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies [J]. Cancer Chemother Pharmacol, 1996,39(1-2):122-130.

共引文献19

同被引文献239

引证文献14

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部